scholarly journals Radiographic remission in rheumatoid arthritis quantified by computer-aided joint space analysis (CASJA): a post hoc analysis of the RAPID 1 trial

2020 ◽  
Vol 22 (1) ◽  
Author(s):  
Alexander Pfeil ◽  
Anica Nussbaum ◽  
Diane M. Renz ◽  
Tobias Hoffmann ◽  
Ansgar Malich ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Certolizumab Pegol ◽  
Joint Space Width ◽  
Joint Space ◽  
Post Hoc Analysis ◽  
Space Analysis ◽  
Computer Aided ◽  
Post Hoc ◽  
Space Width ◽  
Space Distance

Abstract Background The reduction of finger joint space width (JSW) in patients with rheumatoid arthritis (RA) is strongly associated with joint destruction. Treatment with certolizumab pegol (CZP), a PEGylated anti-TNF, has been proven to be effective in RA patients. The computer-aided joint space analysis (CAJSA) provides the semiautomated measurement of joint space width at the metacarpal-phalangeal joints (MCP) based on hand radiographs. The aim of this post hoc analysis of the RAPID 1 trial was to quantify MCP joint space distance (JSD-MCP) measured by CAJSA between baseline and week 52 in RA patients treated with certolizumab pegol (CZP) plus methotrexate (MTX) compared with MTX/placebo. Methods Three hundred twenty-eight patients were included in the post hoc analysis and received placebo plus MTX, CZP 200 mg plus MTX and CZP 400 mg plus MTX. All patients underwent X-rays of the hand at baseline and week 52 as well as assessment of finger joint space narrowing of the MCP using CAJSA (Version 1.3.6; Sectra; Sweden). The joint space width (JSW) was expressed as mean joint space distance of the MCP joints I to V (JSD-MCPtotal). Results The MTX group showed a significant reduction of joint space of − 4.8% (JSD-MCPtotal), whereas in patients treated with CZP 200 mg/MTX and CZP 400 mg/MTX a non-significant change (JSD-MCPtotal + 0.6%) was observed. Over 52 weeks, participants with DAS28 remission (DAS28 ≤ 2.6) exhibited a significant joint space increase of + 3.3% (CZP 200 mg plus MTX) and + 3.9% (CZP pegol 400 mg plus MTX). Conclusion CZP plus MTX did not reduce JSD-MCPtotal estimated by CAJSA compared with MTX/placebo. Furthermore, clinical remission (DAS28 ≤ 2.6) in patients treated with CZP plus MTX was associated with an increasing JSD, indicating radiographic remission in RA.

Effects of leflunomide and methotrexate in rheumatoid arthritis detected by digital X-ray radiogrammetry and computer-aided joint space analysis

2008 ◽  
Vol 29 (3) ◽  
pp. 287-295 ◽  
Author(s):  
Alexander Pfeil ◽  
Julia Lippold ◽  
Thorsten Eidner ◽  
Gabriele Lehmann ◽  
Peter Oelzner ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Joint Space ◽  
X Ray ◽  
Space Analysis ◽  
Computer Aided

scholarly journals Validation of automatic joint space width measurements in hand radiographs in rheumatoid arthritis

2016 ◽  
Vol 3 (4) ◽  
pp. 044502 ◽  
Author(s):  
Olga Schenk ◽  
Yinghe Huo ◽  
Koen L. Vincken ◽  
Mart A. van de Laar ◽  
Ina H. H. Kuper ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Joint Space Width ◽  
Joint Space ◽  
Width Measurements ◽  
Space Width ◽  
Hand Radiographs

Radiographic joint space width in the fingers of patients with rheumatoid arthritis of less than one year's duration

2006 ◽  
Vol 54 (5) ◽  
pp. 1440-1443 ◽  
Author(s):  
Ewan C. Goligher ◽  
Jeffrey Duryea ◽  
Matthew H. Liang ◽  
Frederick Wolfe ◽  
Axel Finckh
Keyword(s):  
Rheumatoid Arthritis ◽  
Joint Space Width ◽  
Joint Space ◽  
Space Width

scholarly journals Tomosynthesis can facilitate accurate measurement of joint space width under the condition of the oblique incidence of X-rays in patients with rheumatoid arthritis

2016 ◽  
Vol 89 (1062) ◽  
pp. 20150967 ◽  
Author(s):  
Yohei Ono ◽  
Rina Kashihara ◽  
Nobutoshi Yasojima ◽  
Hideki Kasahara ◽  
Yuka Shimizu ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Oblique Incidence ◽  
Joint Space Width ◽  
Joint Space ◽  
X Rays ◽  
Space Width

Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial

2012 ◽  
Vol 39 (7) ◽  
pp. 1326-1333 ◽  
Author(s):  
DÉSIRÉE VAN DER HEIJDE ◽  
EDWARD C. KEYSTONE ◽  
JEFFREY R. CURTIS ◽  
ROBERT B. LANDEWÉ ◽  
MICHAEL H. SCHIFF ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Disease Activity Score ◽  
Certolizumab Pegol ◽  
Activity Score ◽  
Clinical Trial Registration ◽  
Low Disease Activity ◽  
Post Hoc Analysis ◽  
Link Type ◽  
Post Hoc

Objective.To determine the relationship between timing and magnitude of Disease Activity Score [DAS28(ESR)] nonresponse (DAS28 improvement thresholds not reached) during the first 12 weeks of treatment with certolizumab pegol (CZP) plus methotrexate, and the likelihood of achieving low disease activity (LDA) at 1 year in patients with rheumatoid arthritis.Methods.In a post-hoc analysis of the RAPID 1 study, patients achieving LDA [DAS28(ESR) ≤ 3.2] at Year 1 were assessed according to DAS28 nonresponse at various timepoints within the first 12 weeks.Results.Seven-hundred eighty-three patients were included (CZP 200 mg, n = 393; CZP 400 mg, n = 390). A total of 86.9% of patients in the CZP 200 mg group had a DAS28 improvement of ≥ 1.2 by Week 12. Of the 13.1% of patients with DAS28 improvement < 1.2 by Week 12, only 2.0% had LDA at Year 1. Failure to achieve LDA at Year 1 depended on timing of nonresponse — 22.3%, 8.4%, and 2.0% of patients with DAS28 improvement < 1.2 by Weeks 1, 6, and 12, respectively, had LDA at Year 1 — and magnitude of initial lack of DAS28 improvement; for example, compared with the patients with DAS28 < 1.2 improvement, fewer patients with DAS28 < 0.6 had LDA at Year 1 (17.4%, 2.4%, and 0.0% at Weeks 1, 6, and 12, respectively).Conclusion.Failure to achieve improvement in DAS28 within the first 12 weeks of therapy was predictive of a low probability of achieving LDA at Year 1. Moreover, the accuracy of the prediction was found to be strongly dependent on the magnitude and timing of the lack of the response. (Clinical Trial Registration Nos. NCT00152386 and NCT00175877).

scholarly journals Rapid Improvement in the Signs and Symptoms of Rheumatoid Arthritis Following Certolizumab Pegol Treatment Predicts Better Longterm Outcomes: Post-hoc Analysis of a Randomized Controlled Trial

2011 ◽  
Vol 38 (6) ◽  
pp. 990-996 ◽  
Author(s):  
EDWARD C. KEYSTONE ◽  
JEFFREY R. CURTIS ◽  
ROY M. FLEISCHMANN ◽  
DANIEL E. FURST ◽  
DINESH KHANNA ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Response ◽  
Clinical Success ◽  
Controlled Trial ◽  
Certolizumab Pegol ◽  
Double Blind ◽  
Post Hoc Analysis ◽  
Radiographic Outcomes ◽  
Post Hoc ◽  
Kinetics Of

Objective.To assess the kinetics of response to certolizumab pegol (CZP), and association between rapid response and longterm outcomes, in patients with active rheumatoid arthritis (RA).Methods.This was a post-hoc analysis of the randomized, double-blind RAPID 1 study in patients who received methotrexate (MTX) and either CZP 200 mg subcutaneously or placebo every 2 weeks for 52 weeks. Clinical and radiographic outcomes at Week 52 were evaluated based on the Disease Activity Score 28 (DAS28) ≥ 1.2 and American College of Rheumatology 20% (ACR20) responses at Week 6 and Week 12.Results.Clinical responses [European League Against Rheumatism (EULAR), DAS28 ≥ 1.2, and ACR20 responses] were rapid in CZP-treated patients. Week 12 DAS28 ≥ 1.2 responders had better clinical and radiographic outcomes at Week 52 compared with nonresponders. Among Week 12 responders, incremental benefit of earlier response was observed: Week 6 DAS28 ≥ 1.2 responders and ACR20 responders had significantly higher ACR response rates and were more likely to achieve remission at Week 52 than Week 12 responders. Patients with a clinical response at Week 6 had faster, more meaningful sustained improvements in patient-derived outcomes than those responding by Week 12 only.Conclusion.Rapid attainment of clinical response in patients with RA is associated with improved longterm outcomes. Analysis of the kinetics of response to CZP during the first 12 weeks of therapy potentially permits informed prediction of clinical success or need to alter treatment. In patients not achieving a clinical response at Week 12 treatment adjustment should be considered. Trial registration NCT00152386.

Automatic Quantification of Radiographic Finger Joint Space Width of Patients With Early Rheumatoid Arthritis

2016 ◽  
Vol 63 (10) ◽  
pp. 2177-2186 ◽  
Author(s):  
Yinghe Huo ◽  
Koen L. Vincken ◽  
Desiree van der Heijde ◽  
Maria J. H. De Hair ◽  
Floris P. Lafeber ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Early Rheumatoid Arthritis ◽  
Joint Space Width ◽  
Joint Space ◽  
Finger Joint ◽  
Automatic Quantification ◽  
Space Width
Sign in / Sign up

Export Citation Format

Share Document